Limits...
RANTES release by human adipose tissue in vivo and evidence for depot-specific differences.

Madani R, Karastergiou K, Ogston NC, Miheisi N, Bhome R, Haloob N, Tan GD, Karpe F, Malone-Lee J, Hashemi M, Jahangiri M, Mohamed-Ali V - Am. J. Physiol. Endocrinol. Metab. (2009)

Bottom Line: Ex vivo release of RANTES was greater from the gastric fat pad compared with omental (P = 0.01) and subcutaneous (P = 0.001) tissue.In conclusion, RANTES is released by human subcutaneous adipose tissue in vivo and in varying amounts by other depots ex vivo.While it appears unlikely that the adipose organ contributes significantly to circulating levels, local implications of this chemokine deserve further investigation.

View Article: PubMed Central - PubMed

Affiliation: Centre for Clinical Pharmacology, Div. of Medicine, University College London, 5 University St., London, UK WC1 6JJ.

ABSTRACT
Obesity is associated with elevated inflammatory signals from various adipose tissue depots. This study aimed to evaluate release of regulated on activation, normal T cell expressed and secreted (RANTES) by human adipose tissue in vivo and ex vivo, in reference to monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) release. Arteriovenous differences of RANTES, MCP-1, and IL-6 were studied in vivo across the abdominal subcutaneous adipose tissue in healthy Caucasian subjects with a wide range of adiposity. Systemic levels and ex vivo RANTES release were studied in abdominal subcutaneous, gastric fat pad, and omental adipose tissue from morbidly obese bariatric surgery patients and in thoracic subcutaneous and epicardial adipose tissue from cardiac surgery patients without coronary artery disease. Arteriovenous studies confirmed in vivo RANTES and IL-6 release in adipose tissue of lean and obese subjects and release of MCP-1 in obesity. However, in vivo release of MCP-1 and RANTES, but not IL-6, was lower than circulating levels. Ex vivo release of RANTES was greater from the gastric fat pad compared with omental (P = 0.01) and subcutaneous (P = 0.001) tissue. Epicardial adipose tissue released less RANTES than thoracic subcutaneous adipose tissue in lean (P = 0.04) but not obese subjects. Indexes of obesity correlated with epicardial RANTES but not with systemic RANTES or its release from other depots. In conclusion, RANTES is released by human subcutaneous adipose tissue in vivo and in varying amounts by other depots ex vivo. While it appears unlikely that the adipose organ contributes significantly to circulating levels, local implications of this chemokine deserve further investigation.

Show MeSH

Related in: MedlinePlus

Monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), and regulated on activation, normal T cell expressed and secreted (RANTES) concentrations in vivo in lean and obese subjects. Fasting arterial and superficial epigastric venous concentrations of RANTES, MCP-1, and IL-6 in lean (n = 11) and obese (n = 8) subjects are shown. Data are shown for individual subjects. Comparisons were carried out by Wilcoxon test, and the P value is shown. MCP-1 concentration in lean (A) and obese (B) subjects, IL-6 concentration in lean (C) and obese (D) subjects, and RANTES concentration in lean (E) and obese (F) subjects are shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2692396&req=5

f1: Monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), and regulated on activation, normal T cell expressed and secreted (RANTES) concentrations in vivo in lean and obese subjects. Fasting arterial and superficial epigastric venous concentrations of RANTES, MCP-1, and IL-6 in lean (n = 11) and obese (n = 8) subjects are shown. Data are shown for individual subjects. Comparisons were carried out by Wilcoxon test, and the P value is shown. MCP-1 concentration in lean (A) and obese (B) subjects, IL-6 concentration in lean (C) and obese (D) subjects, and RANTES concentration in lean (E) and obese (F) subjects are shown.

Mentions: Chemokine concentrations are shown in Table 1. In lean subjects (n = 11), there was significant release of RANTES (P = 0.04) and IL-6 (P = 0.003), but not MCP-1 (P = 0.33), from the abdominal subcutaneous adipose tissue (Table 1, Fig. 1). However, in obese subjects (n = 8), there was significant release of all three molecules by the subcutaneous adipose tissue: RANTES (P = 0.04), IL-6 (P = 0.01) and MCP-1 (P = 0.04) (Table 1, Fig. 1).


RANTES release by human adipose tissue in vivo and evidence for depot-specific differences.

Madani R, Karastergiou K, Ogston NC, Miheisi N, Bhome R, Haloob N, Tan GD, Karpe F, Malone-Lee J, Hashemi M, Jahangiri M, Mohamed-Ali V - Am. J. Physiol. Endocrinol. Metab. (2009)

Monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), and regulated on activation, normal T cell expressed and secreted (RANTES) concentrations in vivo in lean and obese subjects. Fasting arterial and superficial epigastric venous concentrations of RANTES, MCP-1, and IL-6 in lean (n = 11) and obese (n = 8) subjects are shown. Data are shown for individual subjects. Comparisons were carried out by Wilcoxon test, and the P value is shown. MCP-1 concentration in lean (A) and obese (B) subjects, IL-6 concentration in lean (C) and obese (D) subjects, and RANTES concentration in lean (E) and obese (F) subjects are shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2692396&req=5

f1: Monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), and regulated on activation, normal T cell expressed and secreted (RANTES) concentrations in vivo in lean and obese subjects. Fasting arterial and superficial epigastric venous concentrations of RANTES, MCP-1, and IL-6 in lean (n = 11) and obese (n = 8) subjects are shown. Data are shown for individual subjects. Comparisons were carried out by Wilcoxon test, and the P value is shown. MCP-1 concentration in lean (A) and obese (B) subjects, IL-6 concentration in lean (C) and obese (D) subjects, and RANTES concentration in lean (E) and obese (F) subjects are shown.
Mentions: Chemokine concentrations are shown in Table 1. In lean subjects (n = 11), there was significant release of RANTES (P = 0.04) and IL-6 (P = 0.003), but not MCP-1 (P = 0.33), from the abdominal subcutaneous adipose tissue (Table 1, Fig. 1). However, in obese subjects (n = 8), there was significant release of all three molecules by the subcutaneous adipose tissue: RANTES (P = 0.04), IL-6 (P = 0.01) and MCP-1 (P = 0.04) (Table 1, Fig. 1).

Bottom Line: Ex vivo release of RANTES was greater from the gastric fat pad compared with omental (P = 0.01) and subcutaneous (P = 0.001) tissue.In conclusion, RANTES is released by human subcutaneous adipose tissue in vivo and in varying amounts by other depots ex vivo.While it appears unlikely that the adipose organ contributes significantly to circulating levels, local implications of this chemokine deserve further investigation.

View Article: PubMed Central - PubMed

Affiliation: Centre for Clinical Pharmacology, Div. of Medicine, University College London, 5 University St., London, UK WC1 6JJ.

ABSTRACT
Obesity is associated with elevated inflammatory signals from various adipose tissue depots. This study aimed to evaluate release of regulated on activation, normal T cell expressed and secreted (RANTES) by human adipose tissue in vivo and ex vivo, in reference to monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) release. Arteriovenous differences of RANTES, MCP-1, and IL-6 were studied in vivo across the abdominal subcutaneous adipose tissue in healthy Caucasian subjects with a wide range of adiposity. Systemic levels and ex vivo RANTES release were studied in abdominal subcutaneous, gastric fat pad, and omental adipose tissue from morbidly obese bariatric surgery patients and in thoracic subcutaneous and epicardial adipose tissue from cardiac surgery patients without coronary artery disease. Arteriovenous studies confirmed in vivo RANTES and IL-6 release in adipose tissue of lean and obese subjects and release of MCP-1 in obesity. However, in vivo release of MCP-1 and RANTES, but not IL-6, was lower than circulating levels. Ex vivo release of RANTES was greater from the gastric fat pad compared with omental (P = 0.01) and subcutaneous (P = 0.001) tissue. Epicardial adipose tissue released less RANTES than thoracic subcutaneous adipose tissue in lean (P = 0.04) but not obese subjects. Indexes of obesity correlated with epicardial RANTES but not with systemic RANTES or its release from other depots. In conclusion, RANTES is released by human subcutaneous adipose tissue in vivo and in varying amounts by other depots ex vivo. While it appears unlikely that the adipose organ contributes significantly to circulating levels, local implications of this chemokine deserve further investigation.

Show MeSH
Related in: MedlinePlus